Fifty 410 Tirzepatide Review
All-in cost at every dose, what is bundled, what is charged separately, and what Fifty 410 discloses before you pay.
Fifty 410 publishes an entry price of $133 a month all-in and no maintenance-dose figure. We publish no first-year figure for it, because it does not publish a maintenance-dose price and we will not extrapolate one.
Its price rises with the dose, from $133 at the 2.5 mg starter dose to more at the 15 mg ceiling. Budget from the 10 mg row.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
Fifty 410 — what you actually pay, monthly at 2.5 mg
Captured 2026-08-05. Evidence status: source verified.
Commitment and cancellation
Prepaid rate: none published
Cancellation: not published
Visit model: not published
Pharmacy disclosure: not published
Compounded medication is generally not refundable once shipped. Confirm terms in writing before prepaying.
The published figure is a starting price. Fifty 410 does not state, in material we could capture, what the same programme costs at a 10 mg maintenance dose, so we publish the entry price and no maintenance figure. It is therefore excluded from rankings computed at a maintenance dose rather than ranked on a number we would be guessing at.
This programme publishes a starting price but not a price at a maintenance dose. We show the figure it publishes and leave the rest of the ladder blank rather than extrapolating one, which is why it does not appear in rankings computed at 10 mg.
Fifty 410 price at every dose tier
This is the table that decides your year. The advertised figure applies to the starter dose you occupy for roughly four weeks; the row to budget from is 10 mg.
| Dose | All-in monthly | Twelve months at this dose |
|---|---|---|
| 2.5 mg | $133 | $1,596 |
| 5 mg | not published | — |
| 7.5 mg | not published | — |
| 10 mg | not published | — |
| 12.5 mg | not published | — |
| 15 mg | not published | — |
First-year all-in cost
Where Fifty 410 sits in the market
It cannot be ranked on first-year cost, because it does not publish a maintenance-dose price.
What Fifty 410 discloses before you pay
Pharmacy: not published. Visit model: not published. Laboratory requirement: not published. Coaching: not published. Cancellation: not published.
Naming the dispensing pharmacy is the single most useful disclosure a programme can make, because it is the one fact that lets you check a state board register yourself before injecting anything weekly. Fewer than a fifth of the programmes we track publish it.
Who should not choose Fifty 410
Anyone likely to escalate to 12.5 or 15 mg, because the rate rises with you and flat-rate programmes overtake this one at the top of the ladder. Anyone who needs an FDA-approved product, since this is a compounded preparation that FDA does not review for safety, effectiveness or quality before marketing. And anyone who cannot get a straight answer to the pharmacy question.
How the price behaves as your dose climbs
Fifty 410 starts at $133 and rises with your prescription, reaching — at 10 mg. The advertised figure therefore describes roughly four weeks of a twelve-month course. Budget from the 10 mg row, because that is where most of your year happens.
Dose-scaled pricing is not misconduct — more active drug does cost a compounder more. But it means your bill rises exactly as the dose starts working, which inverts the incentive you face and is invisible in any table quoting one number.
What a longer horizon costs here
Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.
| If you maintain at | Per month | One year | Three years |
|---|
Commitment, refunds and what is at risk
No discounted prepaid term is published, which cuts both ways: no lower rate for committing, and no money at risk before you know whether you tolerate the drug. For a first three months that is the safer structure.
Cancellation: not published. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.
What this programme does not publish
Measured against our published criteria, Fifty 410 does not publish: price does not rise as the dose escalates; dispensing pharmacy or prescriber named before purchase; prepaid term and its rate published; state availability published; cancellation terms published. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.
Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.
Seven questions before you enrol
- What is the total in month six at 10 mg, including every fee?
- Which compounding pharmacy fills the prescription, by name and state licence?
- Is the prescribing clinician licensed in my state?
- What is the vial concentration and the beyond-use date?
- Does the quoted rate hold at renewal, or revert?
- What happens if a shipment arrives warm, and who pays for the replacement?
- What notice is required to cancel, and what is refundable before shipment?
None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.
Using it well if you do enrol
Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.
Why a missing price is itself information
A programme that publishes a price is making a claim it can be held to. A programme that reveals cost only after an intake has made a commercial choice: it wants contact details and a medical history before you can compare it against anything. That is legal and common, and worth noticing.
It also makes an honest comparison impossible. Every figure on this site is stated all-in at a named dose, and there is no way to place Fifty 410 on that axis without a number from Fifty 410.
What the alternatives publish
The cheapest tracked route, NexLife, publishes $215 a month all-in at a 10 mg maintenance dose and about $2,580 for a first year. Several publish a full ladder from the starter dose to the ceiling. Those figures can be checked against the provider's own page in under a minute, which is the standard Fifty 410 is being measured against.
What we will not do
Estimate. Several comparison sites carry figures for programmes that publish none, generally by copying an older round-up that copied an earlier one. That is how a promotional rate from two years ago becomes a current price, and it is the most common error in this category.
A blank row is less useful than a number and considerably more honest than a wrong one.
How the price behaves as your dose climbs
Fifty 410 starts at $133 and rises with your prescription, reaching — at 10 mg. The advertised figure therefore describes roughly four weeks of a twelve-month course. Budget from the 10 mg row, because that is where most of your year happens.
Dose-scaled pricing is not misconduct — more active drug does cost a compounder more. But it means your bill rises exactly as the dose starts working, which inverts the incentive you face and is invisible in any table quoting one number.
What a longer horizon costs here
Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.
| If you maintain at | Per month | One year | Three years |
|---|
Commitment, refunds and what is at risk
No discounted prepaid term is published, which cuts both ways: no lower rate for committing, and no money at risk before you know whether you tolerate the drug. For a first three months that is the safer structure.
Cancellation: not published. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.
What this programme does not publish
Measured against our published criteria, Fifty 410 does not publish: price does not rise as the dose escalates; dispensing pharmacy or prescriber named before purchase; prepaid term and its rate published; state availability published; cancellation terms published. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.
Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.
Seven questions before you enrol
- What is the total in month six at 10 mg, including every fee?
- Which compounding pharmacy fills the prescription, by name and state licence?
- Is the prescribing clinician licensed in my state?
- What is the vial concentration and the beyond-use date?
- Does the quoted rate hold at renewal, or revert?
- What happens if a shipment arrives warm, and who pays for the replacement?
- What notice is required to cancel, and what is refundable before shipment?
None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.
Using it well if you do enrol
Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
- FDA — Human Drug Compounding
- FDA — Compounding and the FDA: Questions and Answers
- NABP — State Boards of Pharmacy directory
- FDA — Warning Letters
- DailyMed — FDA prescribing information
- Fifty 410 — pricing page
The source for the figures on this page. If ours and theirs differ, ours is wrong and we want to know. - Wayback Machine lookup for that page
What the archive holds for this URL, so a price captured on 2026-08-05 can be checked against the page as it stood. - FDA — compounded drugs are not FDA-approved
The citation behind every not-FDA-approved statement on this page.
Source and evidence
fifty410.com tirzepatide pricing page, accessed 2026-08-05: compounded tirzepatide programmes starting at $133/month, no subscription, licensed provider consultation and free overnight refrigerated shipping included, monthly and three-month programmes available.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.
Fifty 410: common questions
How much does Fifty 410 cost per month?
$133 all-in at the starter dose. It does not publish a maintenance-dose price, so we publish none. Captured 2026-08-05.
Does Fifty 410 charge a membership fee?
No separate recurring membership is charged on top of the medication price.
What does a first year with Fifty 410 cost?
We publish no first-year figure, because the programme does not publish a maintenance-dose price and we will not extrapolate one.
Is Fifty 410 FDA-approved?
No. It dispenses a compounded preparation, which FDA does not approve or review for safety, effectiveness or quality before marketing.
Can I cancel Fifty 410?
Cancellation terms are not published; ask before enrolling. Compounded medication is generally not refundable once shipped.